胆囊癌DNA甲基化修饰与治疗研究进展  

Research progress on DNA methylation modification and treatment of gallbladder cancer

作　　者：彭海英 李琳[1,2] 李田田 胡海燕 罗梦珍 褚梦缘 廖力微 PENG Haiying;LI Lin;LI Tiantian;HU Haiyan;LUO Mengzhen;CHU Mengyuan;LIAO Liwei(Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University,Yunnan Kunming 650051,China;Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province,Yunnan Kunming 650051,China;Kunming Medical University,Yunnan Kunming 650500,China)

机构地区：[1]昆明医科大学附属延安医院中心实验室,云南昆明650051 [2]云南省肿瘤免疫防治研究重点实验室,云南昆明650051 [3]昆明医科大学,云南昆明650500

出　　处：《现代肿瘤医学》2023年第19期3678-3683,共6页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:82260522);云南省科技厅昆明医科大学应用基础研究联合专项资金(编号:202001AY070001-168)。

摘　　要：胆囊癌是一种罕见但恶性程度极高的肿瘤,早期诊断困难,预后差,多药耐药,发病机制尚不明确。关于胆囊癌的研究主要集中在早期诊断生物标志物和治疗靶点的寻找。胆囊癌被认为是一种表观遗传异常肿瘤,DNA甲基化是其中最常见的一种修饰异常,且随肿瘤进展不断增加,DNA甲基化促进胆囊癌演变及发展,可作为其潜在生物标志物。此外,由于DNA甲基化的可逆性,DNA甲基化抑制剂有望通过与其他药物的联合应用,改善患者预后及耐药性。本研究我们将从DNA甲基化对胆囊癌的调控进行讨论,希望能为胆囊癌的早期诊断、预防和治疗提供一些研究思路。Gallbladder cancer(GBC)is a rare but highly malignant tumor,with difficulty in early diagnosis,poor prognosis and multi-drug resistance,meanwhile,the pathogenesis of this disease has not been clarified yet.The studies on GBC mainly focuses on the search for early diagnosis biomarkers and therapeutic targets.GBC is considered to be atype of tumor with epigenetic abnormalities,in which DNA methylation is one of the most common modifying abnormalities.DNA methylationlevel increases with tumor progression and contributes to the evolution and development of GBC,thus it can serve as a potential biomarker.Furthermore,due to the reversibility of DNA methylation,DNA methylation inhibitors are expected to improve patient prognosis and drug resistance by combining with other drugs.We will discuss the regulation of DNA methylation on GBC,so as to provide someresearch ideas for early diagnosis,prevention and treatment of GBC.

关 键 词：胆囊癌 表观遗传学 DNA甲基化 DNA甲基化抑制剂 

分 类 号：R735.8[医药卫生—肿瘤]